Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ST-02

PreclinicalSmall molecule

UUniversity of British Columbia

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urothelial Carcinoma of the Renal Pelvis and UreterRecruiting

Urothelial Carcinoma of the Renal Pelvis and UreterPreclinical

Recruiting

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Urothelial Carcinoma of the Renal Pelvis and Ureter

NCT06124976

Clinical

Trials by Indication[1]

Urothelial Carcinoma of the Renal Pelvis and Ureter1 trial

A Phase 2/3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) on Ablation of Urothelial Carcinomas in the Upper Urinary Tract

Recruiting·UUniversity of British Columbia·Preclinical·NCT06124976·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ST-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ST-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ST-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of British Columbia

Related News